Innovative Technology Platforms: How They Are Paying Off for Big Pharma and Biotech

Can innovators successfully reverse the decline in pharmaceutical R&D productivity? Although progress in developing new drugs based on genomics and other innovative technology platforms has been slow, recent drug approvals and late-stage clinical developments derived from these technologies are attracting the attention of drug companies and investors. Several companies that have created fully human monoclonal antibodies (MAbs) are yielding results for their corporate partners and owners. Other innovative platforms, particularly those that can yield therapeutic candidates that can be rapidly advanced into the clinic, are also pushing drugs into the marketplace and promise a new and lucrative wave of novel therapeutics that will benefit both industry and patients.

Questions Answered

• Regulatory agencies have recently approved several products that are derived from genomics, fully human MAb technology, and other innovative platforms. Which platform-technology companies have successfully delivered products to the marketplace? What activities are these companies involved in to develop additional new products?
• Pharmaceutical companies are benefitting from innovative technology platforms through corporate partnerships and mergers and acquisitions (M&As) with biotech companies. Which deals between Big Pharma and biotechs have been successful in generating new products? How have these partnerships and M&As evolved?
• An array of biotech companies with various, distinct technology platforms are delivering assets to late-stage development pipelines. Which companies are developing or partnering mature pipelines based on novel technologies? What types of technologies have yielded these results?
• Pharmaceutical companies are now looking to biotechs with technology for creating new types of biotherapeutics. What new technologies will deliver the next generation of biotherapeutics? Which companies are developing these platforms?

Scope

• Genomics: The genomics revolution, corporate partnerships, M&As, contributions to marketplace and clinical pipelines.
• Fully human MAbs: Basic MAb technologies, innovation in fully human MAb development, MAb companies.
• Marketed drugs and development pipelines: Drug approvals, pipeline progress, drug origins, underlying corporate partnerships and M&As.
• Corporate evolution: Business models of innovator companies, corporate partnerships, M&As.
• Maturing technology platforms: Technologies, marketed products, late-stage assets, future development.
• Emerging technology platforms: Innovator companies, next-generation biotherapeutics, corporate partnerships, M&As.

Please note, the PDF e-mail from publisher version of this report is for a global site license.